Tezepelumab administration in moderate-to-severe uncontrolled asthma: Is it all about eosinophils?

Affiliations

¹ Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
² Department of Otolaryngology/Head and Neck Surgery, Hadassah Hebrew University Medical Center and the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
³ Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: francescal@ekmd.huji.ac.il.

Editorial

Pier Giorgio Puzzovio et al. J Allergy Clin Immunol. 2022 May.

. 2022 May;149(5):1582-1584.

doi: 10.1016/j.jaci.2022.01.019. Epub 2022 Feb 8.

¹ Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
² Department of Otolaryngology/Head and Neck Surgery, Hadassah Hebrew University Medical Center and the Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel.
³ Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel. Electronic address: francescal@ekmd.huji.ac.il.

No abstract available

Keywords: Allergic effector unit; TSLP; airway hyperresponsiveness; allergic inflammation; asthma; eosinophils; mast cells.

Comment on

Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.
Diver S, Khalfaoui L, Emson C, Wenzel SE, Menzies-Gow A, Wechsler ME, Johnston J, Molfino N, Parnes JR, Megally A, Colice G, Brightling CE; CASCADE study investigators. Diver S, et al. Lancet Respir Med. 2021 Nov;9(11):1299-1312. doi: 10.1016/S2213-2600(21)00226-5. Epub 2021 Jul 10. Lancet Respir Med. 2021. PMID: 34256031 Clinical Trial.